Pfizer Inc. $PFE Shares Purchased by Adell Harriman & Carpenter Inc.

Adell Harriman & Carpenter Inc. raised its stake in Pfizer Inc. (NYSE:PFE) by 40.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 209,311 shares of the biopharmaceutical company’s stock after purchasing an additional 60,326 shares during the quarter. Adell Harriman & Carpenter Inc.’s holdings in Pfizer were worth $5,074,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of PFE. GKV Capital Management Co. Inc. bought a new stake in Pfizer in the first quarter valued at about $27,000. Curio Wealth LLC boosted its stake in Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares during the period. North Capital Inc. acquired a new position in shares of Pfizer during the first quarter worth approximately $28,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the first quarter worth approximately $28,000. Finally, Harbor Asset Planning Inc. bought a new position in shares of Pfizer in the second quarter valued at $29,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PFE. Morgan Stanley decreased their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. UBS Group reaffirmed a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Finally, Citigroup boosted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $28.13.

Pfizer Stock Down 0.7%

Shares of PFE opened at $24.32 on Thursday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $28.64. The firm has a market cap of $138.26 billion, a P/E ratio of 12.94, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. The firm’s 50-day simple moving average is $24.82 and its 200 day simple moving average is $24.25. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the business posted $0.60 EPS. The business’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer’s dividend payout ratio is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.